Arash Hossein-Nezhad, MD, PhD

Research Assistant Professor, Medicine

Arash Hossein-Nezhad
75 E. Newton St

Biography

Dr. Arash Hossein-nezhad, MD, PhD is a Research Assistant Professor of Endocrinology, Diabetes & Nutrition at Boston University. Dr. Hossein-nezhad is a multidisciplinary scientist with a background in human and molecular genetics, nutrition, endocrinology, cancer, immunology and bioinformatics focused on epigenetic researches. He has extensive experience in research with over 100 peer reviewed publications as well as experience in other research and clinical areas such as bone clinic, microarray and CGH array, liquid chromatography tandem mass spectroscopy, real time PCR, circulating miRNA and microvesicles, Elisa, stem cells and tissue engineering, and next generation sequencing.

Education

  • Tehran University, MD/PhD

Publications

  • Published on 2/19/2025

    Shirvani P, Shirvani A, Holick MF. Mitochondrial Dysfunction and Its Potential Molecular Interplay in Hypermobile Ehlers-Danlos Syndrome: A Scoping Review Bridging Cellular Energetics and Genetic Pathways. Curr Issues Mol Biol. 2025 Feb 19; 47(2). PMID: 39996855.

    Read at: PubMed
  • Published on 2/14/2025

    Shirvani A, Shirvani P, Jonah U, Moore BE, Holick MF. Suspected Mitochondrial Dysfunction and Complex Pathophysiology in Fatal Hypermobile Ehlers-Danlos Syndrome: Insights from a Case Report and Post-Mortem Findings. Biomedicines. 2025 Feb 14; 13(2). PMID: 40002882.

    Read at: PubMed
  • Published on 10/17/2024

    Shirvani P, Shirvani A, Holick MF. Decoding the Genetic Basis of Mast Cell Hypersensitivity and Infection Risk in Hypermobile Ehlers-Danlos Syndrome. Curr Issues Mol Biol. 2024 Oct 17; 46(10):11613-11629. PMID: 39451569.

    Read at: PubMed
  • Published on 5/10/2024

    Maghbooli Z, Shirvani A, Moghadasi AN, Varzandi T, Hamtaei Ghashti S, Sahraian MA. Investigating the effects of 25-hydroxyvitamin D3 on clinical outcomes in multiple sclerosis patients: A randomized, double-blind clinical trial- a pilot study. Mult Scler Relat Disord. 2024 Jul; 87:105673. PMID: 38759424.

    Read at: PubMed
  • Published on 2/8/2024

    Rafiee S, Hossein-Nezhad A, Maghbooli Z, Zargaran A, Emamgholipour S, Ghasemi A, Ahmadi M, Esmaeeli H, Karimi M. Effect of Padzahr Tablet on Biochemical Indices of Bone Remodeling in Postmenopausal Females with Osteopenia: A Randomized Double-Blind Placebo-Controlled Trial. Galen Med J. 2024; 13:1-10. PMID: 39554395.

    Read at: PubMed
  • Published on 10/17/2022

    Charoenngam N, Nasr A, Shirvani A, Holick MF. Hereditary Metabolic Bone Diseases: A Review of Pathogenesis, Diagnosis and Management. Genes (Basel). 2022 Oct 17; 13(10). PMID: 36292765.

    Read at: PubMed
  • Published on 10/13/2021

    Maghbooli Z, Sahraian MA, Jamalimoghadamsiahkali S, Asadi A, Zarei A, Zendehdel A, Varzandi T, Mohammadnabi S, Alijani N, Karimi M, Shirvani A, Holick MF. Treatment With 25-Hydroxyvitamin D3 (Calcifediol) Is Associated With a Reduction in the Blood Neutrophil-to-Lymphocyte Ratio Marker of Disease Severity in Hospitalized Patients With COVID-19: A Pilot Multicenter, Randomized, Placebo-Controlled, Double-Blinded Clinical Trial. Endocr Pract. 2021 Dec; 27(12):1242-1251. PMID: 34653608.

    Read at: PubMed
  • Published on 9/1/2021

    Charoenngam N, Kalajian TA, Shirvani A, Yoon GH, Desai S, McCarthy A, Apovian CM, Holick MF. A pilot-randomized, double-blind crossover trial to evaluate the pharmacokinetics of orally administered 25-hydroxyvitamin D3 and vitamin D3 in healthy adults with differing BMI and in adults with intestinal malabsorption. Am J Clin Nutr. 2021 09 01; 114(3):1189-1199. PMID: 34008842.

    Read at: PubMed
  • Published on 9/1/2021

    Charoenngam N, Kalajian TA, Shirvani A, Yoon GH, Desai S, McCarthy A, Apovian CM, Holick MF. Reply to S Minisola et al. Am J Clin Nutr. 2021 09 01; 114(3):1252-1253. PMID: 34467971.

    Read at: PubMed
  • Published on 6/17/2021

    Holick MF, Shirvani A, Charoenngam N. Fetal Fractures in an Infant with Maternal Ehlers-Danlos Syndrome, CCDC134 Pathogenic Mutation and a Negative Genetic Test for Osteogenesis Imperfecta. Children (Basel). 2021 Jun 17; 8(6). PMID: 34204301.

    Read at: PubMed

View 98 more publications: View full profile at BUMC

View all profiles